DCGO (41) BMGL (53) EUDA (35) ALPS (50) ⌘ Pro Terminal →

P3 Health Partners Inc. (Class A) (PIII) — RQD Stock Rating Cockpit

$4.03 -4.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.99

P3 Health Partners Inc. (Class A) (PIII) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $30.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PIII Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PIII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, P3 Health Partners Inc. (Class A) (NASDAQ: PIII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $4.03 (-4.05% 1D, market cap $30.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PIII ranks #958 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PIII compare to DCGO and BMGL in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), PIII carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DCGO (DocGo Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $27.0M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, PIII leads on earnings multiple (N/A) while PIII leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PIII?

▼

Per PIII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832511), P3 Health Partners Inc. (Class A) generated $1.46B in revenue (-2.8% YoY), -$147.9M in net income, and -$91.2M in free cash flow against $656.6M in total assets and $228.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.99 (-0.92%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PIII)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY PIII SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (33% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 35.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.44-14.2% Next Q

Q2 (-2Q)

Grade E$3.81+1.8% Next Q

Q3 (-1Q)

Grade E$3.88+3.9% Next Q

Current

Grade E$4.03-10.9% Hist 90D α

Trajectory: E (32) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PIII Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PIII currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.62) and Max Pain ($4.23) forces dealer call-delta covering toward $17.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PIII• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PIII Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

35.930 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE16% OF RANGE

L: $2$4.03H: $17

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PIII

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (23)

6/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like PIII

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PIII)

✓Walkthrough of PIII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PIII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.40%🛡️ HOLDING TREND SUPPORT

2026-11-02O $4.03H $4.20L $4.03C $4.03VOL 49.9K

RES: $10.20SUP: $3.02SMA50: $6.62SMA200: $6.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PIII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PIII Butterfly Map → + Track PIII →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PIII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PIII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PIII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PIII)

Health Care Rank #958 of 1016 ⚔️ DCGO vs PIII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PIII vs. DCGO, BMGL, EUDA, ALPS)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, P3 Health Partners Inc. (Class A) (PIII) ranks #958 by composite RQD confidence (24/100, grade E) and #802 by equity capitalization ($30.5M). Within this direct 5-issuer industry benchmark cohort, PIII leads on earnings valuation at N/A trailing P/E, while PIII leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with PIII at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PIII ACTIVE P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$30.5M	Benchmark Subject
DCGO DocGo Inc.	D-	41/100	—	—	-35.0%	-9.59%	$27.0M	/dcgo-vs-piii →
BMGL Basel Medical Group Ltd	D+	53/100	—	—	—	+6.11%	$36.0M	/bmgl-vs-piii →
EUDA EUDA Health Holdings Limited	D-	35/100	—	43.9%	-35.0%	+14.19%	$46.4M	/euda-vs-piii →
ALPS ALPS Group Inc Ordinary Share	D	50/100	—	—	—	+0.03%	$54.1M	/alps-vs-piii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001832511

In its most recent audited fiscal period (FY2025, filed 2025-12-31), P3 Health Partners Inc. (Class A) (PIII) reported GAAP revenue of $1.46B (-2.8% vs. FY2024 revenue of $1.50B , and +15.2% cumulative change since FY2023) , GAAP net income of -$147.9M, operating cash flow of -$91.2M, and free cash flow of -$91.2M (+17.2% YoY). On the balance sheet, PIII closed FY2025 with $656.6M in total assets against $228.4M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.46B	-$147.9M	-$91.2M	-$91.2M	$656.6M	$228.4M
FY2024 (FY)	2024-12-31	$1.50B	-$135.8M	-$110.1M	-$110.1M	$783.4M	$108.9M
FY2023 (FY)	2023-12-31	$1.27B	-$57.8M	-$76.0M	-$76.0M	—	—

3. PIII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PIII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PIII compare to DCGO and BMGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PIII?

Where is PIII trading relative to its 50-day, 200-day, and 52-week technical levels?

PIII last traded at $4.03 (-4.05% on volume of 19,656 shares), positioning the stock -39.12% below its 50-day simple moving average ($6.62) and -38.47% below its 200-day simple moving average ($6.55). Across its 52-week range of $1.52 to $16.89, PIII sits at the 16.3% percentile with a 14-day RSI of 35.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.53 to $4.53).

PIII Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PIII stock right now?

P3 Health Partners Inc. (Class A) (PIII) currently earns a Roarable Rating of E (Strong Sell — SELL) with 24/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PIII's 12-month price target and RQD AI Jury consensus?

PIII's 12-month base price target is $3.41 (range $2.66 to $17.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PIII RQD Cockpit PIII 12M Forecast PIII Earnings & Move PIII Dividends & DRIP PIII Insiders & 13F PIII Whale Options PIII Profit Sankey PIII News & Why

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PIII — P3 Health Partners Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:48:44Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PIII carries an RQD Score of 24 with a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars:

Fundamental Cash Engine: 5 / 20 (ROIC -35%; FCF yield 0%). This is the weakest operating read: the company is not generating return on invested capital or free cash flow relative to the capital employed.
Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). The rating reflects weak institutional support; no holder-level detail is available in the source data.
Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signals are weak; no transaction detail is available in the source data.
Macro Regime Fit: 8 / 20 (Beta 1.0; sector sensitivity). The score is the highest of the five but still reflects limited alignment with the macro regime.
Forensic Balance Sheet: 5 / 20 (Altman Z 0.2; Piotroski F 1/9; Debt/Equity 0.5). The Altman Z-Score of 0.2 and Piotroski F-Score of 1/9 are the core forensic flags.

For a prospective investor evaluating the stock today, these pillars indicate that the primary risk is balance-sheet and cash-generation quality rather than valuation alone. Upside drivers would need to come from a reversal in operating economics, which the current cash-engine and forensic scores do not yet show. Valuation tradeoffs are difficult to frame precisely because forward earnings multiples are not available in source data. Second-order risk is elevated when a company with negative ROIC and a weak Altman Z-Score faces any financing pressure, since the source data does not describe the terms of its debt.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1459.1M	$-270.3M	$-147.9M	N/A	$-91.2M	$25.0M	$228.4M
FY 2024	$1500.5M	$-320.7M	$-135.8M	N/A	$-110.1M	$38.8M	$108.9M
FY 2023	$1266.4M	$-167.9M	$-57.8M	N/A	$-76.0M	N/A	N/A

Per the SEC financials, operating income and net income were negative in each reported period, and free cash flow was negative in all three. Per the market data, the operating margin is -18.5%, the net margin is -10.1%, and the gross margin is 0%. ROIC is -35%. Per the RQD forensic pillar, the Altman Z-Score is 0.2, the Piotroski F-Score is 1 of 9, and the Debt/Equity ratio is 0.5. Balance-sheet posture is weak: cash declined from $38.8M in FY 2024 to $25.0M in FY 2025 while reported debt rose from $108.9M to $228.4M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the feed contains six items, all tagged to PIII:

Chief Clinical Officer appointment (Yahoo Finance; flagged GREEN / CATALYST). The headline reports the appointment of a Chief Clinical Officer, with a second outlet naming Dr. Michael Millie for the role.
TradingView estimates item (flagged GREEN / CATALYST). The headline references earnings estimates; no estimate values are provided in source data.
Seasonal returns charts (Yahoo Finance UK and Yahoo! Finance Canada). The Canada item references agilon health, inc. (AGL), a related-name chart rather than PIII-specific news; the Yahoo Finance UK item is a PIII seasonal chart. The Canada item is flagged YELLOW / MARKET WIRE.
Price-move item (flagged GREEN / CATALYST). The headline reports the stock rising 7.46% to $4.18 on short-term momentum; the summary field is an unrelated site reference and is not informative.

Risk watch items: the news feed contains no disclosed debt refinancing, earnings result, or guidance change. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no supply-chain catalyst is identified.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply_chain value is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be mapped from source data. Sector correlations beyond the Health Care / Medical/Nursing Services classification are not available in source data. A prospective investor should watch for any second-order effect of the negative cash flow and rising reported debt on the company's ability to fund operations, though the source data does not quantify this linkage.

Open Questions

What are the terms, maturities, and covenants of the debt that rose from $108.9M to $228.4M between FY 2024 and FY 2025?
What drove the operating loss of $-270.3M in FY 2025, and what portion is expected to recur?
What are the forward earnings and EBITDA estimates behind the TradingView estimates item?
Who are the institutional and insider holders, and what are their recent position changes?
What is the company's current liquidity runway given cash of $25.0M against negative free cash flow of $-91.2M?

PIII Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for P3 Health Partners Inc. (Class A) (PIII) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PIII Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 13h ago

P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer

Yahoo Finance report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 16h ago

P3 Health Partners Inc. Estimates – NASDAQ:PIII

TradingView report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com UK • 19h ago

P3 Health Partners names Dr. Michael Millie as chief clinical officer

Investing.com UK report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance UK • 22h ago

P3 Health Partners Inc. (PIII) Seasonal returns chart

Yahoo Finance UK report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

P3 Health Partners (PIII) Jumps 7.46% to $4.18 as Buyers Reclaim Short-Term Momentum - Option Breadth

https://www.dars.gov.et/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

agilon health, inc. (AGL) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Fortress Biotech Preferred (FBIOP) Jumps 7.35% to $18.10 as Buyers Press Toward Resistance - TRIN Signal

https://www.siam.in/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

P3 (PIII) Drops -5.05% — Key Support at $3.93 2026-10-24 - BPI Bear Confirmed

https://www.dars.gov.et/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PIII Bull vs. Bear Conversation Board — What's Your Call at $4.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PIII 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.70 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PIII (E • RQD 24/100) a Buy at $4.20?

Welcome to the PIII (P3 Health Partners Inc. (Class A)) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.53 (-16.0%)

Spot @ $4.20

Pump the brakes on PIII — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PIII, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless P3 Health Partners Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.00 (+19.0%)

Spot @ $4.20

PIII cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PIII, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $4.20 (52-wk range $1.52 - $16.89), any beat on forward guidance forces shorts and underweight funds to chase.